About this Research Topic
Pharmacokinetics (PK) and pharmacodynamics (PD) are essential in drug development, providing critical insights into the absorption, distribution, metabolism, and excretion (ADME) of drugs, as well as their pharmacological effects. Drug metabolism, a key component of PK, significantly influences a drug's efficacy, safety, and potential for drug-drug interactions (DDIs)—an increasingly important consideration in the context of polypharmacy.
Recent advancements in modeling, simulation, and in vitro/in vivo methodologies have enabled the integration of PK/PD and drug metabolism data across the entire drug development process. This integrated approach supports the optimization of dosing regimens, early identification of safety risks like DDIs, and more effective translation of preclinical data to clinical outcomes. Regulatory agencies increasingly rely on model-informed drug development (MIDD), highlighting the importance of these integrated approaches in guiding decisions throughout the drug development lifecycle.
Integrating PK/PD and drug metabolism is crucial for streamlining drug development, optimizing clinical trials, and improving regulatory outcomes. This special research topic aims to present innovative research that explores how PK/PD and drug metabolism integration can enhance drug discovery and evaluation from preclinical models to clinical trials. By featuring advanced methodologies, case studies, and translational research, the Research Topic will provide valuable insights for pharmaceutical scientists, clinicians, and regulatory experts.
Recent advancements in modeling, simulation, and in vitro/in vivo methodologies have enabled the integration of PK/PD and drug metabolism data across the entire drug development process. This integrated approach supports the optimization of dosing regimens, early identification of safety risks like DDIs, and more effective translation of preclinical data to clinical outcomes. Regulatory agencies increasingly rely on model-informed drug development (MIDD), highlighting the importance of these integrated approaches in guiding decisions throughout the drug development lifecycle.
Integrating PK/PD and drug metabolism is crucial for streamlining drug development, optimizing clinical trials, and improving regulatory outcomes. This special research topic aims to present innovative research that explores how PK/PD and drug metabolism integration can enhance drug discovery and evaluation from preclinical models to clinical trials. By featuring advanced methodologies, case studies, and translational research, the Research Topic will provide valuable insights for pharmaceutical scientists, clinicians, and regulatory experts.
Keywords: Pharmacokinetics, PK, Pharmacodynamics, PD, ADME, Drug-Drug Interactions, Model-Informed Drug Development, MIDD, Absorption, Distribution, Metabolism, Excretion, Polypharmacy, Dosing Regimens, Transporters, PBPK modeling, PK/PD modeling, Preclinical Evaluation, Clinical Trials
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
